SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
Trial details
- Registry ID
- NCT05303519
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as AB-218; DS-1001b
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)NCT05303519 | NUVB | Phase 3 | Recruiting | 2028-12-01Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |